|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/13/2013 7:39:58 AM
Global healthcare giant Sanofi says it will invest €44m to expand on the manufacture of its insulin products at the Genzyme biotech plant in Waterford where some 500 people are employed. Subject to regulatory approvals, commercial production of Lantus, the No 1 insulin brand at Waterford, should commence in 2016. The IDA-supported investment comes on the heels of a major €150m investment announced last year. “Today’s announcement that Sanofi, a world-leading company in this sector, is investing a further €44m is a major vote of confidence in its Waterford site which employs over 500 people and in the south-east region more generally,” Ireland’s Jobs Minister Richard Bruton, TD, said. “This investment, which comes on top of a €150m investment little more than a year ago, will ensure that this facility can produce the company’s latest product and provides an indication of the Waterford site’s strategic value.”
|
|
|
|
|
|
|
|
|
|
|